UBS Group
ABEO icon

UBS Group’s Abeona Therapeutics ABEO Stock Holding History

UBS Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$105K – 10405
2025
Q4 		$105K Buy
+20,000
New +$101K ﹤0.01% 6886

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's ABEO Position: Q1 2026 in Review

UBS Group increased its Abeona Therapeutics (ABEO) stake by 46% in Q1 2026, buying an estimated $368K and bringing the position to 233,924 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #5523.

UBS Group first reported a position in ABEO in Q4 2015 and has held it in 33 quarters since. The position peaked at $2.18M in Q1 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • UBS Group held 233,924 shares of Abeona Therapeutics worth $1.05M as of Q1 2026.
  • UBS Group bought 73,523 Abeona Therapeutics shares in Q1 2026, an estimated $368K.
  • Abeona Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5523 holding.
  • UBS Group first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • UBS Group's Abeona Therapeutics position peaked at $2.18M in Q1 2018.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.